📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Medico Remedies Approves Unaudited Financial Results for Q3 FY26
Medico Remedies Limited held a board meeting on February 12, 2026, to approve the unaudited standalone financial results for the quarter and period ended December 31, 2025. The meeting was conducted efficiently, lasting only 30 minutes from 5:00 PM to 5:30 PM. The board also reviewed and approved the Auditors' Limited Review Report for the same period. This filing marks the completion of the company's regulatory requirements for the third quarter of the 2025-26 fiscal year.
Key Highlights
Board approved Unaudited Standalone Financial Results for the quarter ended December 31, 2025.
The meeting was held on February 12, 2026, and concluded within 30 minutes.
Auditors' Limited Review Report was formally considered and approved by the board.
Compliance confirmed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements.
💼 Action for Investors
Investors should examine the detailed financial tables to evaluate revenue growth and margin performance compared to previous quarters. Monitor the stock for any price movement following the formal release of these earnings figures.
Medico Remedies Approves Unaudited Financial Results for Quarter Ended Dec 31, 2025
Medico Remedies Limited has officially approved its unaudited standalone financial results for the quarter ended December 31, 2025. The board meeting was held on February 12, 2026, and concluded within 30 minutes, signifying a routine regulatory approval process. While the specific financial figures were not detailed in the summary letter, the announcement confirms the completion of the limited review by auditors. Investors should now look to the detailed financial tables for specific revenue and margin performance.
Key Highlights
Board approved unaudited standalone financial results for the quarter ended December 31, 2025.
The board meeting was conducted on February 12, 2026, from 5:00 P.M. to 5:30 P.M.
The results were submitted along with the Auditors’ Limited Review Report as per SEBI regulations.
The filing covers the performance for the third quarter of the 2025-26 fiscal year.
💼 Action for Investors
Investors should examine the full financial statements for specific growth in net profit and revenue. Compare the Q3 performance against previous quarters to assess the company's operational trajectory.
Medico Remedies Bags ₹37.18 Crore Order from UP Medical Supplies Corporation
Medico Remedies Limited has secured a significant domestic supply order worth approximately ₹37.18 crore from the Uttar Pradesh Medical Supplies Corporation Limited. The contract involves the supply of multiple drugs to the Government of Uttar Pradesh's centralized distribution entity. The company is expected to complete the full supply of the order by October 31, 2026. This government contract provides strong revenue visibility for the company over the next 20 months.
Key Highlights
Total order value is ₹37,17,62,439 (approximately ₹37.18 crore)
Contract awarded by Uttar Pradesh Medical Supplies Corporation Limited, a GoUP entity
The order involves the supply of multiple drugs for state-wide distribution
Project completion timeline is set for October 31, 2026
💼 Action for Investors
Investors should view this as a positive development for revenue growth and monitor the company's ability to maintain margins on government-tendered contracts. Watch for timely execution updates as the October 2026 deadline approaches.
Medico Remedies Secures ₹73.23 Crore Order from UP Medical Supplies Corp
Medico Remedies Limited has bagged a significant domestic order worth ₹73.23 crore from the Uttar Pradesh Medical Supplies Corporation Limited, a Government of Uttar Pradesh entity. The contract involves the supply of Azithromycin 500mg tablets across the state's healthcare network. The company is mandated to complete the full supply of the order by October 31, 2026. This large-scale government contract provides strong revenue visibility and validates the company's standing in the pharmaceutical supply chain.
Key Highlights
Total order value is approximately ₹73,23,16,646 for drug supplies
Contract involves the supply of Azithromycin 500mg tablets to the UP Government
The execution timeline for the full order is set until October 31, 2026
The order is awarded by a domestic government entity with no promoter interest involved
💼 Action for Investors
Investors should view this as a positive development for the company's order book and revenue growth. Monitor the company's ability to maintain margins while executing this large-scale government contract.